metricas

Acta Colombiana de Cuidado Intensivo

Sugerencias
Acta Colombiana de Cuidado Intensivo Resistencia a catecolaminas en el shock séptico: fisiopatología, biomarcadores...
Información de la revista
Vol. 25. Núm. 4.
Páginas 579-746 (Octubre - Diciembre 2025)
Cita
Cita
Compartir
Descargar PDF
Más opciones de artículo
Visitas
2705
Vol. 25. Núm. 4.
Páginas 579-746 (Octubre - Diciembre 2025)
Revisión

Resistencia a catecolaminas en el shock séptico: fisiopatología, biomarcadores y estrategias terapéuticas. Revisión crítica de la literatura

Catecholamine resistance in septic shock: Pathophysiology, biomarkers, and therapeutic strategies. A critical literature review
Visitas
2705
Esteban Armando Ochoa Roblesa,
Autor para correspondencia
eochoarobles@hotmail.com

Autor para correspondencia.
, Carla Alexandra Luzón Duránb
a Unidad de Cuidados Intensivos, Centro de Investigación Clínica, Hospital Pablo Arturo Suárez, Quito, Ecuador
b Unidad de Cuidados Intensivos, Hospital Inglés, Quito, Ecuador
Este artículo ha recibido
Información del artículo
Resumen
Texto completo
Bibliografía
Descargar PDF
Estadísticas
Resumen

El shock séptico, particularmente cuando presenta resistencia a catecolaminas, sigue siendo un desafío significativo en la medicina crítica, asociado con altas tasas de mortalidad y complejidades en el manejo clínico. Este artículo explora en profundidad los mecanismos fisiopatológicos y las estrategias terapéuticas innovadoras para enfrentar esta condición. La resistencia a las catecolaminas se caracteriza por una respuesta vascular disminuida, influenciada por factores como la disfunción endotelial, alteraciones en la señalización receptorial adrenérgica y cambios inflamatorios sistémicos. Además, se discuten los biomarcadores emergentes que permiten un diagnóstico más preciso y una mejor estratificación del riesgo. Se evalúan terapias alternativas, incluyendo el uso de vasopresores no adrenérgicos como la vasopresina y la angiotensinaII, junto con el potencial de los corticosteroides y nuevas modalidades como la hemoadsorción, la terapia de intercambio plasmático y la transfusión de plasma. Este análisis proporciona una perspectiva crítica sobre las opciones terapéuticas que pueden mejorar el manejo del shock séptico resistente a catecolaminas, resaltando la necesidad de un enfoque más personalizado y basado en la evidencia en la atención crítica.

Palabras clave:
Shock séptico
Resistencia a catecolaminas
Vasopresores no catecolaminérgicos
Corticoesteroides
Abstract

Septic shock, particularly when it exhibits catecholamine resistance, continues to pose a significant challenge in critical care medicine, associated with high mortality rates and complexities in clinical management. This chapter delves deeply into the pathophysiological mechanisms and innovative therapeutic strategies to address this condition. Catecholamine resistance is characterized by a diminished vascular response, influenced by factors such as endothelial dysfunction, alterations in adrenergic receptor signaling, and systemic inflammatory changes. Furthermore, emerging biomarkers that allow for more precise diagnosis and better risk stratification are discussed. Alternative therapies are evaluated, including the use of non-catecholamine vasopressors such as vasopressin and angiotensinII, along with the potential of corticosteroids and new modalities such as hemoadsorption, plasma exchange therapy and plasma transfusion. This analysis provides a critical perspective on therapeutic options that can enhance the management of septic shock resistant to catecholamines, highlighting the need for a more personalized and evidence-based approach in critical care.

Keywords:
Septic shock
Catecholamine resistance
Non-catecholamine vasopressors
Corticosteroids

Artículo

Opciones para acceder a los textos completos de la publicación Acta Colombiana de Cuidado Intensivo
Suscriptor
Suscriptor de la revista

Si ya tiene sus datos de acceso, clique aquí.

Si olvidó su clave de acceso puede recuperarla clicando aquí y seleccionando la opción "He olvidado mi contraseña".
Comprar
Comprar acceso al artículo

Comprando el artículo el PDF del mismo podrá ser descargado

Comprar ahora
Contactar
Teléfono para suscripciones e incidencias
De lunes a viernes de 9h a 18h (GMT+1) excepto los meses de julio y agosto que será de 9 a 15h
Llamadas desde España
932 415 960
Llamadas desde fuera de España
+34 932 415 960
E-mail
Bibliografía
[1]
M. Singer, C.S. Deutschman, C. Seymour, M. Shankar-Hari, D. Annane, M. Bauer, et al.
The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3).
JAMA., 315 (2016), pp. 801-810
[2]
E. Antonucci, T. Polo, M. Giovini, M. Girardis, I. Martin-Loeches, N.D. Nielsen, et al.
Refractory septic shock and alternative wordings: A systematic review of literature.
J Crit Care., 75 (2023), pp. 154258
[3]
B. Zhu, J. Jiang, H. Yu, L. Huang, D. Zhou.
Effect of norepinephrine, vasopressin, and dopamine for survivals of the elderly with sepsis and pre-existing heart failure.
[4]
P.R. Barbosa Evora, A.C. Celotto, A.A. Sumarelli Albuquerque, P. Martinez Évora.
Endothelial dysfunction in distributive shock.
Vasoplegic Endothelial Dysfunction, Springer, (2021), pp. 45-51 http://dx.doi.org/10.1007/978-3-030-74096-2_7
[5]
E. Barth, P. Radermacher, C. Thiemermann, S. Weber, M. Georgieff, G. Albuszies.
Role of inducible nitric oxide synthase in the reduced responsiveness of the myocardium to catecholamines in a hyperdynamic, murine model of septic shock.
Crit Care Med., 34 (2006), pp. 307-313
[6]
F. Senatore, P. Balakumar, G. Jagadeesh.
Dysregulation of the renin-angiotensin system in septic shock: Mechanistic insights and application of angiotensinII in clinical management.
Pharmacol Res., 174 (2021),
[7]
A. Enguix-Armada, R. Escobar-Conesa, A.G. de la Torre, M.V. de la Torre-Prados.
Usefulness of several biomarkers in the management of septic patients: C-reactive protein, procalcitonin, presepsin and mid-regional pro-adrenomedullin.
Clin Chem Lab Med., 54 (2016), pp. 163-168
[8]
B. Venkatesh, A.K. Khanna, J. Cohen.
Less is more: Catecholamine-sparing strategies in septic shock.
Intensive Care Med., 45 (2019), pp. 1810-1812
[9]
M. Conrad, P. Perez, C. Thivilier, B. Levy.
Early prediction of norepinephrine dependency and refractory septic shock with a multimodal approach of vascular failure.
J Crit Care., 30 (2015), pp. 739-743
[10]
P. Ma, J. Liu, F. Shen, X. Liao, M. Xiu, H. Zhao, et al.
Individualized resuscitation strategy for septic shock formalized by finite mixture modeling and dynamic treatment regimen.
[11]
A. Chaba, A. Zarbock, L.G. Forni, J. Hästbacka, E. Korneva, G. Landoni, et al.
AngiotensinII for catecholamine resistant vasodilatory shock in patients with acute kidney injury: A post-hoc analysis of the ATHOS-3 Trial.
[12]
N.D. Jakowenko, J. Murata, B.J. Kopp, B.L. Erstad.
Influence of timing and catecholamine requirements on vasopressin responsiveness in critically ill patients with septic shock.
J Intensive Care Med., 37 (2022), pp. 1512-1519
[13]
T.E. Albertson, J.A. Chenoweth, J.C. Lewis, J.V. Pugashetti, C.E. Sandrock, B.M. Morrissey.
The pharmacotherapeutic options in patients with catecholamine-resistant vasodilatory shock.
Expert Rev Clin Pharmacol., 15 (2022), pp. 959-976
[14]
S. Baykan, M. Bicakcioglu, N. Bulut, N. Yucel, Y. Ersoy, N. Kibrislioglu Uysal, et al.
Hydrocortisone may act through the angiotensinII receptor-2 level in patients with catecholamine-resistant septic shock.
Minerva Anestesiol., 89 (2023), pp. 298-305
[15]
J.K. Lee, S. Lee, J. Samide, C. Chun.
1661: Efficacy of early versus late addition of vasopressin to catecholamines in septic shock.
[16]
R. Domizi, S. Calcinaro, S. Harris, C. Beilstein, C. Boerma, J.D. Chiche, et al.
Relationship between norepinephrine dose, tachycardia and outcome in septic shock: A multicentre evaluation.
J Crit Care., 57 (2020), pp. 185-190
[17]
G.L. Sacha, S.W. Lam, L. Wang, A. Duggal, A.J. Reddy, S.R. Bauer.
Association of catecholamine dose, lactate, and shock duration at vasopressin initiation with mortality in patients with septic shock.
Crit Care Med., 50 (2022), pp. 614-623
[18]
R.Q. Yao, D.M. Xia, L.X. Wang, G.S. Wu, Y.B. Zhu, H.Q. Zhao, et al.
Clinical efficiency of vasopressin or its analogs in comparison with catecholamines alone on patients with septic shock: A systematic review and meta-analysis.
Front Pharmacol., 11 (2020), pp. 563
[19]
L. Zhong, X.W. Ji, H.L. Wang, G.M. Zhao, Q. Zhou, B. Xie.
Non-catecholamine vasopressors in the treatment of adult patients with septic shock — Evidence from meta-analysis and trial sequential analysis of randomized clinical trials.
J Intensive Care., 8 (2020), pp. 83
[20]
G.M. Khan, R.P. Rashid, T. Ahmed.
Understanding the pathophysiology of vasoplegia following cardiopulmonary bypass: A comprehensive narrative review.
Cardiovasc J., 16 (2024), pp. 92-97
[21]
A. Kimmoun, N. Ducrocq, B. Levy.
Mechanisms of vascular hyporesponsiveness in septic shock.
Curr Vasc Pharmacol., 11 (2013), pp. 139-149
[22]
M. Carrara, M. Ferrario, B. Bollen Pinto, A. Herpain.
The autonomic nervous system in septic shock and its role as a future therapeutic target: A narrative review.
Ann Intensive Care., 11 (2021), pp. 80
[23]
B. Levy, S. Collin, N. Sennoun, N. Ducrocq, A. Kimmoun, P. Asfar, et al.
Vascular hyporesponsiveness to vasopressors in septic shock: From bench to bedside.
Intensive Care Med., 36 (2010), pp. 2019-2029
[24]
A. Belletti, G. Landoni, V.V. Lomivorotov, A. Oriani, S. Ajello.
Adrenergic downregulation in critical care: molecular mechanisms and therapeutic evidence.
J Cardiothorac Vasc Anesth., 34 (2020), pp. 1023-1041
[25]
T.A. Nakada, J.A. Russell, J.H. Boyd, R. Aguirre-Hernandez, K.R. Thain, S.A. Thair, et al.
beta2-Adrenergic receptor gene polymorphism is associated with mortality in septic shock.
Am J Respir Crit Care Med., 181 (2010), pp. 143-149
[26]
S. Isac, T. Isac, M.D. Tanasescu, B. Pavel, C.V. Andreescu, A.G. Badea, et al.
The omics complexity in sepsis: The limits of the personalized medicine approach.
J Pers Med., 14 (2024), pp. 225
[27]
R. Bruning, H. Dykes, T.W. Jones, N.B. Wayne, A. Sikora Newsome.
Beta-adrenergic blockade in critical illness.
Front Pharmacol., 12 (2021),
[28]
E. De Montmollin, J. Aboab, A. Mansart, D. Annane.
Bench-to-bedside review: β-Adrenergic modulation in sepsis.
Crit Care., 13 (2009), pp. 230
[29]
P. Kümpers, A. Lukasz, S. David, R. Horn, C. Hafer, R. Faulhaber-Walter, et al.
Excess circulating angiopoietin-2 is a strong predictor of mortality in critically ill medical patients.
Crit Care., 12 (2008),
[30]
Y. Chi, S. Yu, J. Yin, D. Liu, M. Zhuo, X. Li.
Role of angiopoietin/Tie2 system in sepsis: A potential therapeutic target.
Clin Appl Thromb Hemost., 30 (2024),
[31]
A. Piotti, D. Novelli, J.M.T.A. Meessen, D. Ferlicca, S. Coppolecchia, A. Marino, et al.
Endothelial damage in septic shock patients as evidenced by circulating syndecan-1, sphingosine-1-phosphate and soluble VE-cadherin: A substudy of ALBIOS.
Crit Care., 25 (2021), pp. 1-12
[32]
K. Suzuki, H. Okada, K. Sumi, H. Tomita, R. Kobayashi, T. Ishihara, et al.
Serum syndecan-1 reflects organ dysfunction in critically ill patients.
[33]
A. Sauer, K. Stahl, B. Seeliger, P.D. Wendel-Garcia, F. Lehmann, J.J. Schmidt, et al.
The effect of therapeutic plasma exchange on the inflammatory response in septic shock: A secondary analysis of the EXCHANGE-1 trial.
Intensive Care Med Exp., 13 (2025), pp. 18
[34]
X. Chu, C. Di, P. Chang, L. Li, Z. Feng, S. Xiao, et al.
Lactylated histone H3K18 as a potential biomarker for the diagnosis and predicting the severity of septic shock.
[35]
C. Kong, Y. Zhu, X. Xie, J. Wu, M. Qian.
Six potential biomarkers in septic shock: A deep bioinformatics and prospective observational study.
[36]
S. Jiang, Y. Li, Y. Zhao, M. Wu, B. Mi, L. Liu, et al.
Genetic polymorphisms, biomarkers and signaling pathways associated with septic shock: From diagnosis to therapeutic targets.
[37]
D. Velissaris, N. Zareifopoulos, V. Karamouzos, E. Karanikolas, C. Pierrakos, I. Koniari, et al.
Presepsin as a diagnostic and prognostic biomarker in sepsis.
Cureus., 13 (2021),
[38]
C. Geven, M. Kox, P. Pickkers.
Adrenomedullin and adrenomedullin-targeted therapy as treatment strategies relevant for sepsis.
Front Immunol., 9 (2018), pp. 292
[39]
R. Marino, J. Struck, A.S. Maisel, L. Magrini, A. Bergmann, S.D. Somma.
Plasma adrenomedullin is associated with short-term mortality and vasopressor requirement in patients admitted with sepsis.
Crit Care., 18 (2014), pp. R34
[40]
M.F. Abasıyanık, K. Wolfe, H. van Phan, J. Lin, B. Laxman, S.R. White, et al.
Ultrasensitive digital quantification of cytokines and bacteria predicts septic shock outcomes.
Nat Commun., 11 (2020), pp. 2607
[41]
I. Coloretti, A. Genovese, J.P. Teixeira, A. Cherian, R. Ferrer, G. Landoni, et al.
AngiotensinII therapy in refractory septic shock: Which patient can benefit most? A narrative review.
J Anesth Analg Crit Care., 4 (2024), pp. 13
[42]
L. Evans, A. Rhodes, W. Alhazzani, M. Antonelli, C.M. Coopersmith, C. French, et al.
Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021.
Intensive Care Med., 47 (2021), pp. 1181-1247
[43]
R. Ferrer, P. Castro, C. Lorencio, J. Monclou, P. Marcos, A. Ochagavia, et al.
Ten take-home messages on vasopressin use in critically ill patients.
Med Intensiva., 48 (2024), pp. 704-713
[44]
A.C. Gordon, A.J. Mason, N. Thirunavukkarasu, G.D. Perkins, M. Cecconi, M. Cepkova, et al.
Effect of early vasopressin vs norepinephrine on kidney failure in patients with septic shock: The VANISH randomized clinical trial.
JAMA., 316 (2016), pp. 509-518
[45]
J.A. Russell, K.R. Walley, J. Singer, A.C. Gordon, P.C. Hébert, D.J. Cooper, et al.
Vasopressin versus norepinephrine infusion in patients with septic shock.
N Engl J Med., 358 (2008), pp. 877-887
[46]
M. Ibarra-Estrada, E. Kattan, P. Aguilera-González, L. Sandoval-Plascencia, U. Rico-Jauregui, C.A. Gómez-Partida, et al.
Early adjunctive methylene blue in patients with septic shock: A randomized controlled trial.
Crit Care., 27 (2023), pp. 1-10
[47]
C.C. Zhao, Y.J. Zhai, Z.J. Hu, Y. Huo, Z.Q. Li, G.J. Zhu.
Efficacy and safety of methylene blue in patients with vasodilatory shock: A systematic review and meta-analysis.
Front Med (Lausanne)., 9 (2022),
[48]
H.M. Brokmeier, T.G. Seelhammer, S.D. Nei, D.J. Gerberi, K.C. Mara, E.D. Wittwer, et al.
Hydroxocobalamin for vasodilatory hypotension in shock: A systematic review with meta-analysis for comparison to methylene blue.
J Cardiothorac Vasc Anesth., 37 (2023), pp. 1757-1772
[49]
L. Huang, Q. Huang, W. Ma, H. Yang.
Understanding hemodynamic incoherence: Mechanisms, phenotypes, and implications for treatment.
[50]
J.L. Vélez-Páez, D. Torres-Carpio, M.L. Avellanas-Chavala.
Esteroides, sepsis y shock séptico: de la plausibilidad biológica a la evidencia actual. Revisión narrativa.
Acta Colomb Cuid Intensivo., 25 (2025), pp. 261-370
[51]
M. Heymann, R. Schorer, A. Putzu.
Mortality and adverse events of hemoadsorption with CytoSorb® in critically ill patients: A systematic review and meta-analysis of randomized controlled trials.
Acta Anaesthesiol Scand., 66 (2022), pp. 1037-1050
[52]
C. Orban, A. Bratu, M. Agapie, T. Borjog, M. Jafal, R.M. Sima, et al.
To hemoadsorb or not to hemoadsorb — Do we have the answer yet? An updated meta-analysis on the use of CytoSorb in sepsis and septic shock.
Biomedicines, 13 (2025), pp. 180
[53]
D. Steindl, T. Schroeder, A. Krannich, J. Nee.
Hemoadsorption in the management of septic shock: A systematic review and meta-analysis.
J Clin Med., 14 (2025), pp. 2285
[54]
K. Kogelmann, T. Hübner, M. Drüner, D. Jarczak.
Impact of CytoSorb hemoadsorption therapy on fluid balance in patients with septic shock.
J Clin Med., 13 (2024), pp. 294
[55]
V. Kuklin, M. Sovershaev, J. Bjerner, P. Keith, L.K. Scott, O.M.T. Thomas, et al.
Influence of therapeutic plasma exchange treatment on short-term mortality of critically ill adult patients with sepsis-induced organ dysfunction: A systematic review and meta-analysis.
[56]
P.D. Keith, A.H. Wells, J. Hodges, S.H. Fast, A. Adams, L.K. Scott.
The therapeutic efficacy of adjunct therapeutic plasma exchange for septic shock with multiple organ failure: A single-center experience.
[57]
M. Dietrich, T. Hölle, L.D. Lalev, M. Loos, F.C.F. Schmitt, M.O. Fiedler, et al.
Plasma transfusion in septic shock — A secondary analysis of a retrospective single-center cohort.
J Clin Med., 11 (2022), pp. 4367
[58]
J.J. Chen, P.C. Lai, T.H. Lee, Y.T. Huang.
Blood purification for adult patients with severe infection or sepsis/septic shock: A network meta-analysis of randomized controlled trials.
Crit Care Med., 51 (2023), pp. 1777-1789
[59]
M. Scheck, M. Velten, S. Klaschik, M. Soehle, S. Frede, J. Gehlen, et al.
Differential modulation of endothelial cell function by fresh frozen plasma.
Life Sci., 254 (2020),
[60]
M.S. Kravitz, N. Kattouf, I.J. Stewart, A.A. Ginde, E.P. Schmidt, N.I. Shapiro.
Plasma for prevention and treatment of glycocalyx degradation in trauma and sepsis.
[61]
N.E. Clausen, C.S. Meyhoff, H.H. Henriksen, A. Lindhardt, F.C. Pott, T.B. Lunen, et al.
Plasma as endothelial rescue in septic shock: A randomized, phase 2a pilot trial.
Transfusion (Paris)., 64 (2024), pp. 1653-1661
[62]
N.E. Clausen, C.S. Meyhoff, H.H. Henriksen, A. Lindhardt, F.C. Pott, T.B. Lunen, et al.
Plasma as endothelial rescue in septic shock: A randomized, phase 2a pilot trial.
Transfusion (Paris)., 64 (2024), pp. 1653-1661
[63]
E.J. Kelly, E.E. Ziedins, B.C. Carney, L.T. Moffatt, J.W. Shupp.
Endothelial dysfunction is dampened by early administration of fresh frozen plasma in a rodent burn shock model.
J Trauma Acute Care Surg., 97 (2024), pp. 520-528
[64]
C.L. Ge, L.N. Zhang, Y.H. Ai, W. Chen, Z.W. Ye, Y. Zou, et al.
Effect of β-blockers on mortality in patients with sepsis: A propensity-score matched analysis.
Front Cell Infect Microbiol., 13 (2023),
[65]
S. Rehberg, S. Frank, V. Černý, R. Cihlář, R. Borgstedt, G. Biancofiore, et al.
Landiolol for heart rate control in patients with septic shock and persistent tachycardia. A multicenter randomized clinical trial (Landi-SEP).
Intensive Care Med., 50 (2024), pp. 1622-1634
[66]
G.A. Vásquez-Tirado, C.V. Quispe-Castañeda, E.D. Meregildo-Rodríguez, M. Cuadra-Campos, N.M. Segura-Plasencia, Y.K. Arbayza-Avalos, et al.
Association of beta blockers and mortality in adults with septic shock: Systematic review and meta-analysis of randomized clinical trial.
Front Med (Lausanne)., 11 (2024),
[67]
V. Vazgiourakis, K. Mantzarlis, D. Makris.
Landiolol in patients with septic shock.
Intensive Care Med., 51 (2024), pp. 221
[68]
M. Mokhlesian, F. Heydari, S.J. Boskabadi, A.G. Baradari, A. Ajami, R. Alizadeh-Navaei.
The effect of dexmedetomidine on inflammatory factors and clinical outcomes in patients with septic shock: A randomized clinical trial.
[69]
A.R. Ezz AL-regal, E.A. Ramzy, A.A. Allah Atia, M.M. Emara.
Dexmedetomidine for reducing mortality in patients with septic shock: A randomized controlled trial (DecatSepsis).
Chest., 166 (2024), pp. 1394-1405
[70]
H. Huang, Q. Li, Q. Lin, Z. Gong, L. Chen, F. Chen, et al.
The relationship between dexmedetomidine administration and prognosis in patients with sepsis-induced coagulopathy: A retrospective cohort study.
Front Pharmacol., 15 (2024),
[71]
X. Huang, C. He.
The efficacy of dexmedetomidine for septic shock: A meta-analysis of randomized controlled trials.
Medicine., 102 (2023),
[72]
C. Wang, Q. Chen, P. Wang, W. Jin, C. Zhong, Z. Ge, et al.
The effect of dexmedetomidine as a sedative agent for mechanically ventilated patients with sepsis: A systematic review and meta-analysis.
Front Med (Lausanne)., 8 (2021),
[73]
A. Dargent, A. Bourredjem, M. Jacquier, J. Bohe, L. Argaud, B. Levy, et al.
Dexmedetomidine to reduce vasopressor resistance in refractory septic shock: α2 Agonist Dexmedetomidine for REfractory Septic Shock (ADRESS): A double-blind randomized controlled pilot trial.
Crit Care Med., 53 (2025), pp. e884-e896
[74]
I. Coloretti, M. Tosi, E. Biagioni, S. Busani, M. Girardis.
Management of sepsis in the first 24 hours: Bundles of care and individualized approach.
Semin Respir Crit Care Med., 45 (2024), pp. 503-509
asdasdasd
Opciones de artículo
Herramientas